Company Description
Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs.
The company offers its products for the treatment of cancer, neurodegenerative diseases, and autoimmune disorders.
Its lead product candidate is pepinemab, a humanized monoclonal antibody that completed and planned Phase 1b/2 clinical trials for the treatment of non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), Huntington's disease, Alzheimer's disease, osteosarcoma, and melanoma.
The company is also developing VX5, a human antibody to CXCL13 that is in preclinical development for the treatment of MS and for other autoimmune disorders.
Vaccinex, Inc. was incorporated in 2001 and is headquartered in Rochester, New York.
| Country | United States |
| IPO Date | Aug 9, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 37 |
| CEO | Dr. Maurice Zauderer Ph.D. |
Contact Details
Address: 1895 Mount Hope Avenue Rochester, New York United States | |
| Website | https://www.vaccinex.com |
Stock Details
| Ticker Symbol | VCNX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001205922 |
| CUSIP Number | 918640103 |
| ISIN Number | US9186403013 |
| Employer ID | 16-1603202 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Maurice Zauderer Ph.D. | Co-Founder, Chief Executive Officer, President & Director |
| Dr. Elizabeth E. Evans Ph.D. | Chief Operating Officer and Senior Vice President of Discovery & Translational Medicine |
| Jill Sanchez CPA | Chief Financial Officer |
| Dr. Ernest S. Smith Ph.D. | Senior Vice President of Research & Chief Scientific Officer |
| Dr. John E. Leonard Ph.D. | Senior Vice President of Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 17, 2024 | 8-K | Current Report |
| Nov 18, 2024 | SC 13D/A | [Amend] Filing |
| Nov 18, 2024 | 4 | Filing |
| Nov 18, 2024 | 4 | Filing |
| Nov 14, 2024 | 8-K | Current Report |
| Nov 14, 2024 | 10-Q | Quarterly Report |
| Nov 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Oct 25, 2024 | 424B3 | Filing |
| Oct 16, 2024 | S-3 | Filing |
| Oct 09, 2024 | 8-K | Current Report |